This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-4452v1 69/11/4742    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Cao, Z. Articles by Giovanella, B. PubMed PubMed Citation Articles by Cao, Z. Articles by Giovanella, B.

Crystalline Camptothecin-20(S)-O-Propionate Hydrate:A Novel Anticancer Agent with Strong Activity against 19 Human Tumor Xenografts

CHRISTUS Stehlin Foundation for Cancer Research, Houston, Texas

Requests for reprints: Zhisong Cao, CHRISTUS Stehlin Foundation for Cancer Research, 1918 Chenevert Street, Houston, TX 77003. Phone: 713-756-5750; Fax: 713-756-5783; E-mail: zcao{at}stehlin.org.

Key Words: Camptothecin • CZ48 • Anticancer activity • Toxicity • Therapeutic index

To find a more effective and less toxic chemotherapeutic agent, we have successfully prepared crystalline camptothecin-20(S)-O-propionate hydrate (CZ48) by reacting camptothecin with propionic anhydride using concentrated sulfuric acid as catalyst. The biological effectiveness of this new anticancer agent was evaluated by using xenografts of human cancers in nude mice as the testing models. The extensive treatment of 21 human tumors with various dose levels of CZ48 has shown that this agent is highly effective against many different human tumors tested with a striking lack of toxicity. Of the 21 human tumor lines tested, 9 regressed, 5 were <10% of the control, 3 were <20%, and 2 were <40%. Two tumors did not respond. The total response rate was 90% (19 of 21). No toxicity was observed in mice. The effective doses required to achieve the positive response varied from 100 to 1,000 mg/kg/d depending on the tumors. The maximum tolerated dose was not reached because of the nontoxic nature of the drug in mice. Thus, this compound has a much wider therapeutic index compared with that of the existing anticancer drugs currently in use. [Cancer Res 2009;69(11):4742–9]